The Fort Worth Press - Avant Technologies and Partner, Ainnova, Receive FDA Pre-Submission Meeting Date for Company’s Vision AI Platform Technology

USD -
AED 3.672502
AFN 64.999801
ALL 81.123148
AMD 360.500471
ANG 1.789785
AOA 917.000256
ARS 1545.2224
AUD 1.432593
AWG 1.8
AZN 1.699323
BAM 1.744435
BBD 2.013263
BDT 124.343874
BGN 1.747831
BHD 0.37725
BIF 3004
BMD 1
BND 1.278581
BOB 12.140484
BRL 5.482997
BSD 0.999585
BTN 94.811201
BWP 13.808328
BYN 2.953267
BYR 19600
BZD 2.01032
CAD 1.395745
CDF 2309.99985
CHF 0.819297
CLF 0.024881
CLP 979.229915
CNY 6.648303
CNH 6.67311
COP 3211.19
CRC 454.527211
CUC 1
CUP 23.989333
CVE 98.874952
CZK 21.7741
DJF 177.719832
DKK 6.68478
DOP 60.250267
DZD 136.047703
EGP 55.341795
ERN 15
ETB 162.433359
EUR 0.89441
FJD 2.24675
FKP 0.745229
GBP 0.745525
GEL 2.594972
GGP 0.745229
GHS 11.649649
GIP 0.745229
GMD 73.500741
GNF 8800.000044
GTQ 7.642051
GYD 209.539525
HKD 7.845775
HNL 26.869372
HRK 6.76901
HTG 131.015506
HUF 326.079501
IDR 18136.55
ILS 3.161404
IMP 0.745229
INR 94.73755
IQD 1515.298819
IRR 1879654.000336
ISK 121.830148
JEP 0.745229
JMD 158.843703
JOD 0.709046
JPY 158.244498
KES 129.939703
KGS 87.449904
KHR 4085.000211
KMF 439.999912
KPW 899.999961
KRW 1345.590138
KWD 0.31144
KYD 0.832995
KZT 452.368741
LAK 22530.000318
LBP 89550.000227
LKR 332.306128
LRD 170.225022
LSL 16.636267
LTL 2.95274
LVL 0.60489
LYD 6.414756
MAD 9.828437
MDL 18.057593
MGA 4514.054577
MKD 55.025816
MMK 2099.543828
MNT 3601.136904
MOP 8.078026
MRU 40.503405
MUR 47.296346
MVR 15.460069
MWK 1736.999996
MXN 18.60742
MYR 4.077023
MZN 63.858728
NAD 16.636267
NGN 1344.610252
NIO 36.783168
NOK 9.224075
NPR 151.697565
NZD 1.77751
OMR 0.384497
PAB 0.999799
PEN 3.467019
PGK 4.482837
PHP 63.508022
PKR 276.504083
PLN 3.95665
PYG 5917.059487
QAR 3.653878
RON 4.778806
RSD 105.237022
RUB 81.526084
RWF 1478.412502
SAR 3.764439
SBD 8.058206
SCR 13.716903
SDG 601.505751
SEK 9.795495
SGD 1.28118
SHP 0.748335
SLE 22.899227
SLL 20969.504398
SOS 571.280766
SRD 37.5795
STD 20697.981008
STN 21.85227
SVC 8.746259
SYP 13001.999685
SZL 16.630915
THB 33.779783
TJS 9.191303
TMT 3.5
TND 2.987517
TOP 2.40776
TRY 49.986598
TTD 6.761717
TWD 32.797203
TZS 2643.297997
UAH 45.650373
UGX 4277.693292
UYU 40.190338
UZS 11944.718217
VES 887.4798
VND 25766
VUV 118.901474
WST 2.774695
XAF 586.694254
XAG 0.02045
XAU 0.000256334342
XCD 2.70255
XCG 1.80143
XDR 0.707052
XOF 586.694254
XPF 106.371498
YER 236.198647
ZAR 16.66562
ZMK 9001.208965
ZMW 20.242167
ZWL 321.999592
SSP 5745.200537
MXV 2.095014
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

Avant Technologies and Partner, Ainnova, Receive FDA Pre-Submission Meeting Date for Company’s Vision AI Platform Technology
Avant Technologies and Partner, Ainnova, Receive FDA Pre-Submission Meeting Date for Company’s Vision AI Platform Technology

Avant Technologies and Partner, Ainnova, Receive FDA Pre-Submission Meeting Date for Company’s Vision AI Platform Technology

LAS VEGAS, NEVADA / ACCESS Newswire / May 6, 2025 / Avant Technologies Inc. (OTCQB:AVAI) ("Avant" or the "Company"), and its JV partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced that the U.S. Food and Drug Administration (FDA) has scheduled its pre-submission meeting with Ainnova's executives and its CRO, Fortrea, for July 7, 2025, to discuss a range of items related to the Company's planned clinical trial of its Vision AI platform in the early detection of diabetic retinopathy.

Text size:

Vinicio Vargas, Chief Executive Officer at Ainnova and a member of the Board of Directors of Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova to advance and commercialize Ainnova's technology portfolio, said, "We are forever grateful for the opportunity to meet with the U.S. FDA to discuss our planned clinical trial. These meetings will give us the direction that we'll need for success and to support our FDA 510(k) submission to obtain clearance from the FDA to market our technology in the U.S."

"We will use this pre-submission meeting to determine a host of items, including the ideal number of clinical sites, the number of total patients needed, and to learn if the FDA will approve our protocol for the planned clinical trial. These are all crucial for both Avant and Ainnova in determining the exact costs and a timetable."

AAC has the worldwide licensing rights for Ainnova's technology portfolio. The licensing rights include the U.S., where the FDA regulates drug and medical device development, so the success of Ainnova's interactions with the FDA are paramount to marketing the technology portfolio in the United States. Entering the U.S. market will unlock significant commercial potential, and this early engagement with the FDA ensures AAC can do so with speed, credibility, and a validated product.

About Ainnova Tech, Inc.

Ainnova is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas. Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce Vision AI - our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions.

About Avant Technologies Inc.

Avant Technologies Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare. With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology.

More information about Avant can be found at https://avanttechnologies.com

You can also follow us on social media at:

https://twitter.com/AvantTechAI

https://www.linkedin.com/company/avant-technologies-ai

https://www.facebook.com/AvantTechAI

https://www.youtube.com/@AvantTechAI

Forward-Looking Statements

Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release.

Contact:

Avant Technologies Inc.
[email protected]

SOURCE: Avant Technologies



View the original press release on ACCESS Newswire

C.Dean--TFWP